PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
60.05%
R&D growth while Biotechnology reduces spending. Peter Lynch would examine strategic differences.
231.77%
G&A change of 231.77% versus flat Biotechnology overhead. Walter Schloss would verify efficiency.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
121.69%
Operating expenses growth exceeding 1.5x Biotechnology median of 0.67%. Jim Chanos would check for waste.
-100.00%
Total costs reduction while Biotechnology median is -29.45%. Seth Klarman would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
D&A reduction while Biotechnology median is -100.00%. Seth Klarman would investigate efficiency.
-127.89%
EBITDA decline while Biotechnology median is -1.69%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
-121.69%
Operating income decline while Biotechnology median is 1.34%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
-17.94%
Other expenses reduction while Biotechnology median is -12.00%. Seth Klarman would investigate advantages.
-139.60%
Pre-tax income decline while Biotechnology median is -2.12%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-139.60%
Net income decline while Biotechnology median is -2.65%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
-131.82%
EPS decline while Biotechnology median is 0.71%. Seth Klarman would investigate causes.
-131.82%
Diluted EPS decline while Biotechnology median is 0.71%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.